# A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV)

> **NCT07365371** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine** · enrollment: 174 (estimated)

## Conditions studied

- Polypoidal Choroidal Vasculopathy (PCV)
- Neovascular Age Related Macular Degeneration (AMD)

## Interventions

- **DRUG:** Aflibercept Intravitreous Injection

## Key facts

- **NCT ID:** NCT07365371
- **Lead sponsor:** Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 174 (ESTIMATED)
- **Last updated:** 2026-01-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07365371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07365371, "A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07365371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*